Directory · 2026
Global Antibody-Drug Conjugate Developers
201
developers
22
countries
165 / 28 / 8
solid tumours / both / haematology
This is the public layer. The full map adds phase, payloads, linkers, targets, funding and partnerships.
Request the full market mapThe Directory
Build your view
Tick a dimension to add it as a column. The data lives behind the request below.
Base columns
Add columns
Showing 201 of 201
| What they develop | Expand | |||
|---|---|---|---|---|
3H (Shanghai) Pharmaceuticals | Auristatin-payload ADC developer targeting FGFR2b. | Shanghai, China | Solid tumours | |
AbbVie | Maytansinoid-payload ADC developer targeting Folate receptor alpha (FRa/FOLR1). | North Chicago, USA | Both | |
ABL Bio / NEOK Bio | Topoisomerase-1 inhibitor-payload ADC developer targeting B7-H3 x ROR1 (bispecific). | Seongnam, South Korea | Solid tumours | |
AbTis / Dong-A ST | ADC developer targeting CLDN18.2 (Claudin-18.2). | Seoul, South Korea | Solid tumours | |
ADC Therapeutics SA | PBD-payload ADC developer targeting CD19. | Epalinges, Switzerland | Both | |
Adcendo ApS | Topoisomerase I inhibitor-payload ADC developer targeting uPARAP / Endo180. | Copenhagen, Denmark | Solid tumours | |
Adcentrx Therapeutics | Auristatin-payload ADC developer targeting Nectin-4. | San Diego, CA, USA | Solid tumours | |
Adcytherix SAS | Topo-I-payload ADC developer targeting Undisclosed. | Marseille, France | Solid tumours | |
Aimed Bio | Topoisomerase-I inhibitor-payload ADC developer targeting n/d (undisclosed solid-tumor target). | Seoul, South Korea | Solid tumours | |
Akari Therapeutics | Spliceosome modulator - novel cytotoxic mechanism distinct from tubulin-payload ADC developer targeting Trop2. | London, UK | Solid tumours | |
Akeso Inc | N-payload ADC developer targeting Trop2 / Nectin4 (bispecific). | Zhongshan, Guangdong, China | Solid tumours | |
Alentis Therapeutics | Tubulin inhibitor-payload ADC developer targeting Claudin-1 (CLDN1). | Basel, Switzerland | Solid tumours | |
Allink Bio (Shanghai Allink Biotherapeutics Co., Ltd.) | ADC developer targeting EGFR / cMET (bispecific). | Shanghai, China | Solid tumours | |
Alphamab Oncology | Topoisomerase I inhibitor-payload ADC developer targeting HER2 (biparatopic - two non-overlapping epitopes). | Suzhou, Jiangsu, China | Both | |
Alteogen, Inc. | Auristatin-payload ADC developer targeting HER2. | Daejeon, South Korea | Solid tumours | |
ALX Oncology Inc. | Topoisomerase I inhibitor-payload ADC developer targeting EGFR. | South San Francisco, USA | Solid tumours | |
Ambrx, Inc. | Microtubule inhibitor-payload ADC developer targeting HER2. | San Diego, USA | Solid tumours | |
AmMax Bio | Topoisomerase-1 inhibitor-payload ADC developer targeting n/d (AmMax proprietary monoclonal antibody; target antigen undisclosed). | Redwood City, CA, USA | Both | |
Angiex | Microtubule inhibitor-payload ADC developer targeting TM4SF1. | Cambridge, MA, USA | Solid tumours | |
Antengene Corporation | Auristatin-payload ADC developer targeting Claudin 18.2 (CLDN18.2). | Shanghai, China | Solid tumours | |
Antikor Biopharma | Auristatin-payload ADC developer targeting HER2. | Stevenage, UK | Solid tumours | |
Araris Biotech | Auristatin-payload ADC developer targeting CD79b. | Wadenswil, Switzerland | Haematology | |
ArriVent BioPharma | ADC developer targeting n/d (genuinely undisclosed in all primary/trade sources checked; GI-focused). | Newtown Square, PA, USA | Solid tumours | |
Astellas Pharma Inc. | Auristatin-payload ADC developer targeting Nectin-4. | Tokyo, Japan | Solid tumours | |
AstraZeneca | Topoisomerase I inhibitor-payload ADC developer targeting HER2 (ERBB2). | Cambridge, UK | Both | |
Auricula Biosciences, Inc. | N-payload ADC developer targeting n/d - patient population is defined as KRAS-mutant solid tumors, but the antibody's actual cell-surface target antigen is not disclosed in any source found (KRAS itself is intracellular and not a plausible direct ADC binding target). | USA | Solid tumours | |
Avenzo Therapeutics, Inc. | ADC developer targeting EGFR/HER3 (bispecific). | San Diego, USA | Solid tumours | |
Axcynsis Therapeutics Pte Ltd | DNA-binding-payload ADC developer targeting CLDN6. | Singapore, Singapore | Solid tumours | |
BeiGene (BeOne Medicines) | Topoisomerase I inhibitor-payload ADC developer targeting B7-H4. | Beijing, China | Solid tumours | |
BigHat Biosciences, Inc. | ADC developer targeting CDH17. | Menlo Park, USA | Solid tumours | |
Bio-Thera Solutions | Topoisomerase I inhibitor-payload ADC developer targeting Folate receptor alpha (FR-alpha). | Guangzhou, China | Solid tumours | |
BioAtla, Inc. | Auristatin-payload ADC developer targeting AXL. | San Diego, USA | Solid tumours | |
BIOCAD | Maytansinoid-payload ADC developer targeting HER2. | St. Petersburg, Russia | Solid tumours | |
BioCity Biopharmaceutics Co., Ltd. | N-payload ADC developer targeting CDH3 (Cadherin-3 / P-cadherin). | Wuxi, Jiangsu, China | Solid tumours | |
Biocytogen (百奥赛图) | Topoisomerase I inhibitor-payload ADC developer targeting B7H3 / PTK7 (bispecific). | Beijing, China | Solid tumours | |
BiOneCure Therapeutics, Inc. | Bispecific ADC developer targeting TROP2. | Germantown, MD, USA | Solid tumours | |
BioNTech SE | Topoisomerase I inhibitor-payload ADC developer targeting HER2. | Mainz, Germany | Solid tumours | |
BlissBio (Bliss Biopharmaceutical (Hangzhou) Co., Ltd.) | Eribulin-payload ADC developer targeting HER2. | Hangzhou, Zhejiang, China | Solid tumours | |
Boan Biotech | Auristatin-payload ADC developer targeting Claudin 18.2 (CLDN18.2). | Yantai, Shandong, China | Solid tumours | |
Boehringer Ingelheim | Topo-I-payload ADC developer targeting Undisclosed (described as playing a significant role in tumor growth, metastasis and therapeutic resistance across multiple malignancies). | Ingelheim, Germany | Solid tumours | |
Bristol Myers Squibb | Topoisomerase I inhibitor-payload ADC developer targeting EGFR x HER3 (bispecific). | Princeton, USA | Solid tumours | |
Byondis B.V. | Duocarmycin-payload ADC developer targeting HER2. | Nijmegen, Netherlands | Both | |
Callio Therapeutics | Dual-payload-payload ADC developer targeting HER2. | Seattle, WA, USA | Solid tumours | |
Cantargia | Tubulin inhibitor-payload ADC developer targeting IL1RAP. | Lund, Sweden | Solid tumours | |
CatenaBio | Dual: tubulin inhibitor and topo-1 inhibitor-payload ADC developer targeting TROP2. | Berkeley, CA, USA | Solid tumours | |
Celltrion | Topoisomerase-I inhibitor-payload ADC developer targeting Nectin-4. | Incheon, South Korea | Solid tumours | |
Changchun GeneScience Pharmaceutical Co., Ltd. | ADC developer targeting EGFR x HER2 (bispecific). | Changchun, China | Solid tumours | |
Chengdu Kanghong Pharmaceutical Group / Kanghong Biotechnology | Dual: topoisomerase-1 inhibitor + RNA-polymerase-II inhibitor-payload ADC developer targeting TROP2 (single cell-surface antibody target; two distinct intracellular payload mechanisms). | Chengdu, China | Solid tumours | |
Chia Tai Tianqing (CTTQ) / Sino Biopharmaceutical | Topoisomerase I inhibitor-payload ADC developer targeting HER2 (biparatopic - two distinct extracellular domain epitopes, ECD2 and ECD4). | Hong Kong, China | Solid tumours | |
Chiome Bioscience Inc. | PBD-payload ADC developer targeting DLK1. | Tokyo, Japan | Solid tumours | |
Chong Kun Dang | ADC developer targeting c-MET. | Seoul, South Korea | Solid tumours | |
Chugai Pharmaceutical Co., Ltd. | ADC developer targeting n/d (one Chugai-selected target, undisclosed). | Tokyo, Japan | Solid tumours | |
CIS Biopharma | Topo-1 inhibitor-payload ADC developer targeting CD171/L1CAM. | Bubendorf, Switzerland | Solid tumours | |
Corbus Pharmaceuticals Holdings, Inc. | Auristatin-payload ADC developer targeting Nectin-4. | Norwood, MA, USA | Solid tumours | |
Crescent Biopharma | ADC developer targeting ITGB6 (integrin beta-6). | Waltham, MA, USA | Solid tumours | |
CrossBridge Bio | Dual: topo-1 inhibitor-payload ADC developer targeting TROP2. | Houston, TX, USA | Solid tumours | |
CSPC Pharmaceutical Group (Megalith / ZhongQi / Ouyi / Innovation) | Auristatin-payload ADC developer targeting EGFR. | Shijiazhuang, Hebei, China | Both | |
CStone Pharmaceuticals | PBD-payload ADC developer targeting ROR1. | Suzhou, China | Both | |
CytomX Therapeutics, Inc. | Maytansinoid-payload ADC developer targeting CD166. | South San Francisco, USA | Both | |
Daiichi Sankyo Co., Ltd. | Global ADC leader with the largest DXd (topoisomerase-1) franchise: two approved products in HER2 and TROP2 and a deep next-generation pipeline | Tokyo, Japan | Both | |
Day One Biopharmaceuticals, Inc. | Auristatin-payload ADC developer targeting B7-H4. | South San Francisco, USA | Solid tumours | |
Debiopharm | ADC developer targeting HER3/HER2 (bispecific). | Lausanne, Switzerland | Solid tumours | |
DualityBio (Duality Biologics) | Topoisomerase I inhibitor-payload ADC developer targeting HER2. | Shanghai, China | Solid tumours | |
Earendil Labs | Topoisomerase I inhibitor-payload ADC developer targeting CEACAM5 / CDH17 (bispecific). | Unconfirmed, China | Solid tumours | |
Eisai Co., Ltd. | Eribulin-payload ADC developer targeting Folate receptor alpha (FRα). | Tokyo, Japan | Solid tumours | |
Elevation Oncology | Auristatin-payload ADC developer targeting Claudin 18.2 (CLDN18.2). | New York, NY, USA | Solid tumours | |
Eli Lilly and Company | Topoisomerase I inhibitor-payload ADC developer targeting Nectin-4. | Indianapolis, IN, USA | Solid tumours | |
Ellipses Pharma Ltd | Eribulin-payload ADC developer targeting B7H3. | London, UK | Solid tumours | |
Emergence Therapeutics AG | Topo-I-payload ADC developer targeting Nectin-4. | Duisburg, Germany | Solid tumours | |
Endeavor BioMedicines, Inc. | ADC developer targeting HER3. | San Diego, USA | Solid tumours | |
Evopoint Biosciences Co., Ltd. | Topoisomerase I inhibitor-payload ADC developer targeting Claudin 18.2 (CLDN18.2). | Suzhou, China | Solid tumours | |
Exelixis, Inc. | Auristatin-payload ADC developer targeting 5T4. | Alameda, CA, USA | Solid tumours | |
Experimental Drug Development Centre (EDDC), A*STAR | Auristatin-payload ADC developer targeting Tumor-specific N-glycosylated epitope conserved on CEACAM5 and CEACAM6. | Singapore, Singapore | Solid tumours | |
Foreseen Biotechnology | Topoisomerase I inhibitor-payload ADC developer targeting n/d (undisclosed novel tumor-associated antigen, identified via AI-powered proteomics screening). | Unconfirmed, China | Solid tumours | |
Fosun Pharma (Shanghai Fosun Pharmaceutical Group) | Auristatin-payload ADC developer targeting HER2. | Shanghai, China | Solid tumours | |
GeneQuantum Healthcare | Topoisomerase I inhibitor-payload ADC developer targeting HER2. | Suzhou, China | Solid tumours | |
Genmab A/S | Auristatin-payload ADC developer targeting Tissue Factor (TF/F3). | Copenhagen, Denmark | Solid tumours | |
Genome and Company | Auristatin-payload ADC developer targeting BCAM (CD239). | Seongnam, South Korea | Solid tumours | |
Gilead Sciences, Inc. | Topoisomerase I inhibitor-payload ADC developer targeting Trop-2 (TACSTD2). | Foster City, CA, USA | Solid tumours | |
Glenmark Pharmaceuticals Ltd / Ichnos Glenmark Innovation (IGI) | Topoisomerase I inhibitor-payload ADC developer targeting HER2. | Mumbai, India | Solid tumours | |
GlycoNex | ADC developer targeting Branched Lewis B/Y (bLeB/Y) tumor-associated glycan. | Hsinchu, Taiwan | Solid tumours | |
Glykos Finland | Auristatin-payload ADC developer targeting CD33. | Espoo, Finland | Haematology | |
GSK | Auristatin-payload ADC developer targeting BCMA (TNFRSF17). | London, UK | Both | |
Hangzhou Adcoris Biopharma | Topoisomerase I inhibitor-payload ADC developer targeting 5T4 (TPBG). | Hangzhou, China | Solid tumours | |
Hangzhou DAC Biotech | Topoisomerase I inhibitor-payload ADC developer targeting CD56 (NCAM1). | Hangzhou, China | Both | |
Hanmi Pharmaceutical (Beijing) | Topoisomerase-I inhibitor-payload ADC developer targeting PD-L1 x B7-H3 (tetravalent bispecific). | Beijing, China | Solid tumours | |
Hansoh Pharma | Topoisomerase I inhibitor-payload ADC developer targeting B7-H3. | Lianyungang, China | Solid tumours | |
Harbour BioMed (HBM Holdings) / Nona Biosciences | Topoisomerase I inhibitor-payload ADC developer targeting Mesothelin (MSLN). | Shanghai, China | Solid tumours | |
Heidelberg Pharma AG | Amanitin-payload ADC developer targeting BCMA. | Ladenburg, Germany | Both | |
Huadong Medicine (Hangzhou Zhongmei Huadong Pharmaceutical) | Maytansinoid-payload ADC developer targeting Folate receptor alpha (FRalpha). | Hangzhou, China | Both | |
Hummingbird Bioscience Pte Ltd | Topoisomerase I inhibitor-payload ADC developer targeting HER3. | Singapore, Singapore | Solid tumours | |
IDEAYA Biosciences, Inc. | Topoisomerase I inhibitor-payload ADC developer targeting DLL3. | South San Francisco, CA, USA | Solid tumours | |
Iksuda Therapeutics Ltd. | PBD-payload ADC developer targeting CD19. | Newcastle upon Tyne, England, UK | Both | |
Immunome, Inc. | Topoisomerase I inhibitor-payload ADC developer targeting ROR1. | Bothell, WA, USA | Both | |
Inatherys | ADC developer targeting CD71 / transferrin receptor 1 (TfR1). | Evry-Courcouronnes, France | Haematology | |
Innate Pharma | Topo-I-payload ADC developer targeting Nectin-4. | Marseille, France | Solid tumours | |
InnoCare Pharma | N-payload ADC developer targeting CDH17 (cadherin-17). | Beijing, China | Solid tumours | |
Innolake Biopharm (英诺湖医药) | Eribulin-payload ADC developer targeting B7-H3 (CD276). | Hangzhou, China | Solid tumours | |
Innovent Biologics | Topoisomerase I inhibitor-payload ADC developer targeting CLDN18.2. | Suzhou, China | Solid tumours | |
Inspirna | Auristatin-payload ADC developer targeting MERTK (MER proto-oncogene tyrosine kinase). | New York, NY, USA | Both | |
IntoCell | Duocarmycin-payload ADC developer targeting B7-H3. | Seongnam, South Korea | Solid tumours | |
InxMed (Ying Shi Bio) | Topoisomerase I inhibitor-payload ADC developer targeting Integrin alphaVbeta6 (ITGB6). | Shanghai, China | Solid tumours | |
Ipsen | Topo-I-payload ADC developer targeting LRRC15. | Paris, France | Solid tumours | |
Jiangsu Hengrui Pharmaceuticals (Hengrui Medicine / Hengrui Pharma) | Topoisomerase I inhibitor-payload ADC developer targeting HER2 (ERBB2). | Shanghai, China | Both | |
Johnson & Johnson (Janssen) | Auristatin-payload ADC developer targeting HER2 (ERBB2). | New Brunswick, NJ, USA | Both | |
Junshi Biosciences (Shanghai Junshi Bioscience Co., Ltd.) | Tubulin inhibitor-payload ADC developer targeting Claudin 18.2 (CLDN18.2). | Shanghai, China | Solid tumours | |
Kanaph Therapeutics | ADC developer targeting cMET x EGFR (bispecific). | Seoul, South Korea | Solid tumours | |
Kelun-Biotech (Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.) | Topoisomerase I inhibitor-payload ADC developer targeting TROP2 (TACSTD2). | Chengdu, Sichuan, China | Solid tumours | |
KeyMed Biosciences | Auristatin-payload ADC developer targeting Claudin 18.2 (CLDN18.2). | Chengdu, China | Solid tumours | |
Kivu Bioscience Inc. | Topoisomerase I inhibitor-payload ADC developer targeting PTK7. | San Francisco, USA | Solid tumours | |
Kyinno Biotechnology (凯茵诺生物) | Topoisomerase I inhibitor-payload ADC developer targeting EGFR / MET (bispecific). | Unconfirmed, China | Solid tumours | |
Kyowa Kirin Co., Ltd. | PBD-payload ADC developer targeting TIM-3. | Tokyo, Japan | Haematology | |
LaNova Medicines | Auristatin-payload ADC developer targeting Claudin 18.2 (CLDN18.2). | Shanghai, China | Solid tumours | |
Lepu Biopharma Co., Ltd. | Auristatin-payload ADC developer targeting EGFR. | Shanghai, China | Both | |
LigaChem Biosciences, Inc. | Auristatin-payload ADC developer targeting TROP2. | Daejeon, South Korea | Solid tumours | |
MabCare Therapeutics | ADC developer targeting PTK7. | Shanghai, China | Solid tumours | |
Mablink Bioscience | ADC developer targeting Folate receptor alpha (FRa). | Lyon, France | Solid tumours | |
Mabsoft Therapeutics (Shanghai) Co., Ltd. | N-payload ADC developer. | Shanghai, China | Solid tumours | |
Mabwell (Shanghai Mabwell Bioscience Co., Ltd.) | Auristatin-payload ADC developer targeting Nectin-4. | Shanghai, China | Solid tumours | |
MacroGenics, Inc. | Topoisomerase I inhibitor-payload ADC developer targeting B7-H3. | Rockville, MD, USA | Solid tumours | |
MBrace Therapeutics, Inc. | Auristatin-payload ADC developer targeting EphA5. | San Diego, CA, USA | Solid tumours | |
MediLink Therapeutics (Suzhou) Co., Ltd. | Topoisomerase I inhibitor-payload ADC developer targeting B7-H3. | Suzhou, China | Solid tumours | |
Menarini Ricerche S.p.A. | Maytansinoid-payload ADC developer targeting CD205 (Ly75). | Pomezia, Italy | Both | |
Merck & Co., Inc. (MSD outside US/Canada) | Topoisomerase I inhibitor-payload ADC developer targeting TROP2. | Rahway, NJ, USA | Both | |
Merck KGaA, Darmstadt | Topo-I-payload ADC developer targeting CEACAM5. | Darmstadt, Germany | Solid tumours | |
Mersana Therapeutics | Auristatin-payload ADC developer targeting B7-H4. | Cambridge, MA, USA | Solid tumours | |
Merus | Antibody-drug conjugate developer. | Utrecht, Netherlands | Solid tumours | |
Minghui Pharmaceutical Ltd. | Topoisomerase I inhibitor-payload ADC developer targeting B7-H3. | Hangzhou, China | Solid tumours | |
Multitude Therapeutics | Topoisomerase I inhibitor-payload ADC developer targeting CD44v9. | Unconfirmed, China | Solid tumours | |
Myricx Bio | NMTi - novel-payload ADC developer targeting B7-H3. | London, UK | Solid tumours | |
Mythic Therapeutics, Inc. | Auristatin-payload ADC developer targeting cMET. | Waltham, MA, USA | Solid tumours | |
Nanjing Leads Biolabs (南京维立志博) | Topoisomerase I inhibitor-payload ADC developer targeting CDH17. | Nanjing, Jiangsu, China | Solid tumours | |
Nanolattix Biotechnology Co., Ltd. | ADC developer targeting Tissue Factor (TF). | China | Solid tumours | |
Navrogen, Inc. | N-payload ADC developer targeting Mesothelin (MSLN). | Cheyney, PA, USA | Solid tumours | |
NextCure, Inc. | Topoisomerase I inhibitor-payload ADC developer targeting B7-H4. | Beltsville, MD, USA | Solid tumours | |
Novartis | NMT inhibitor - novel cytotoxic payload class disrupting protein myristoylation-payload ADC developer targeting B7-H3. | Basel, Switzerland | Solid tumours | |
Novatim Immune Therapeutics (Zhejiang) Co., Ltd. | Auristatin-payload ADC developer targeting c-Met / EGFR (bispecific). | Zhejiang province, China | Solid tumours | |
Novelty Nobility, Inc. | Auristatin-payload ADC developer targeting c-Kit (CD117). | Seoul, South Korea | Solid tumours | |
OBI Pharma, Inc. | Topoisomerase I inhibitor-payload ADC developer targeting TROP2. | Taipei, Taiwan | Solid tumours | |
Ona Therapeutics | Tubulin inhibitor-payload ADC developer targeting Confidential (highly expressed in HR+/HER2- breast cancer; upregulated in treatment-resistant tumors). | Barcelona, Spain | Solid tumours | |
Oncomatryx Biopharma S.L. | Synthetic cytolysin-payload ADC developer targeting FAP (Fibroblast Activation Protein) - cancer-associated-fibroblast/tumor-microenvironment target. | Derio, Bizkaia, Spain | Solid tumours | |
OnCusp Therapeutics, Inc. | Topoisomerase I inhibitor-payload ADC developer targeting CDH6. | Princeton, NJ, USA | Solid tumours | |
Ono Pharmaceutical Co., Ltd. | ADC developer targeting L1CAM (L1 cell adhesion molecule). | Osaka, Japan | Solid tumours | |
Oqory, Inc. | ADC developer targeting TROP2. | San Diego, CA, USA | Solid tumours | |
Peptron | ADC developer targeting MUC1. | Daejeon, South Korea | Solid tumours | |
Pfizer Inc. | Auristatin-payload ADC developer targeting Nectin-4. | New York, NY, USA | Both | |
Pheon Therapeutics | ADC developer targeting n/d (internalizable single-pass transmembrane protein, highly over-expressed in multiple solid tumors, low healthy-tissue expression). | London, UK | Solid tumours | |
PinotBio | Topo-1 inhibitor-payload ADC developer targeting Trop2. | Seongnam, South Korea | Solid tumours | |
Prestige Biopharma IDC | N-payload ADC developer targeting n/d - undisclosed. | Seoul, South Korea | Solid tumours | |
Pyramid Biosciences | Topoisomerase I inhibitor-payload ADC developer targeting TROP2. | Boston, MA, USA | Solid tumours | |
Pyxis Oncology, Inc. | ADC developer targeting Extradomain-B of fibronectin (EDB+FN) - an extracellular-matrix, non-cellular structural antigen. | Boston, MA, USA | Solid tumours | |
Qilu Pharmaceutical Co., Ltd. | Topoisomerase I inhibitor-payload ADC developer targeting Claudin 6 (CLDN6). | Jinan, Shandong, China | Solid tumours | |
Qurient Therapeutics | ADC developer targeting n/d - undisclosed. | Seoul, South Korea | Solid tumours | |
Radiance Biopharma, Inc. | Auristatin-payload ADC developer targeting c-MET and EGFR (bispecific). | San Diego, CA area, USA | Both | |
RemeGen (Yantai RemeGen Co., Ltd.) | Tubulin inhibitor-payload ADC developer targeting HER2 (ERBB2). | Yantai, Shandong, China | Solid tumours | |
Roche / Genentech | Maytansinoid-payload ADC developer targeting HER2. | South San Francisco, CA, USA | Both | |
Ryvu Therapeutics | Antibody-drug conjugate developer. | Krakow, Poland | Solid tumours | |
Samjin Pharmaceutical | NAMPT inhibitor - non-classical cytotoxic payload class, not on the project's standard example list, but a genuine cytotoxic small molecule per peer-reviewed literature-payload ADC developer targeting HER2. | Seoul, South Korea | Solid tumours | |
Samsung Bioepis Co., Ltd. | ADC developer targeting Nectin-4. | Incheon, South Korea | Solid tumours | |
Sanofi | Topoisomerase I inhibitor-payload ADC developer targeting CEACAM5. | Paris, France | Solid tumours | |
Shandong New Time Pharmaceutical Co., LTD | ADC developer targeting Nectin-4. | Linyi, Shandong, China | Solid tumours | |
Shanghai Affinity Biopharmaceutical Co., Ltd. | ADC developer targeting IL-2 (atypical target for an ADC - IL-2 is normally a soluble cytokine rather than a cell-surface tumor antigen; precise binding mechanism not independently verified). | Shanghai, China | Solid tumours | |
Shanghai Escugen Biotechnology Co., Ltd | ADC developer targeting TROP2. | Shanghai, China | Solid tumours | |
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Topoisomerase I inhibitor-payload ADC developer targeting TROP2. | Shanghai, China | Solid tumours | |
Shanghai Henlius Biotech, Inc. | N-payload ADC developer targeting HER2. | Shanghai, China | Solid tumours | |
Shanghai Huaota Biopharmaceutical Co., Ltd. | ADC developer targeting CD73. | Shanghai, China | Solid tumours | |
Shanghai Runshi Pharmaceutical Technology Co., Ltd | Auristatin-payload ADC developer targeting HER2. | Shanghai, China | Solid tumours | |
Shanghai Tangling Biomedicine | ADC developer targeting TROP-2. | Shanghai, China | Solid tumours | |
Sidewinder Therapeutics | Bispecific ADC developer targeting n/d (dual-targeting design: one undisclosed tumor-driver receptor + one undisclosed internalizing receptor). | San Francisco Bay Area, USA | Solid tumours | |
Simcere Zaiming | Topoisomerase I inhibitor-payload ADC developer targeting CDH6. | Nanjing, China | Solid tumours | |
Solve Therapeutics | ADC developer targeting n/d ('distinct membrane receptor protein selectively expressed on multiple solid-tumor malignancies'). | San Diego, CA, USA | Solid tumours | |
Sorrento Therapeutics / Scintilla Pharmaceuticals | Auristatin-payload ADC developer targeting CD38. | San Diego, CA, USA | Solid tumours | |
SOTIO Biotech | ADC developer targeting CDH17 (Cadherin-17). | Prague, Czech Republic | Solid tumours | |
Stipple Bio, Inc. | ADC developer targeting n/d (tumor-specific cell-surface epitope, precise antigen undisclosed). | Cambridge, MA, USA | Solid tumours | |
Sun Pharma Advanced Research Company Ltd (SPARC) | ADC developer targeting MUC1 (SEA domain, targeting the epitope exposed only when both MUC1 alpha and beta chains remain intact). | Mumbai, India | Solid tumours | |
Sutro Biopharma, Inc. | Hemiasterlin-class tubulin-payload ADC developer targeting Folate receptor alpha (FOLR1). | South San Francisco, CA, USA | Both | |
Suzhou Hepius Therapeutics | Auristatin-payload ADC developer targeting ALPP/ALPPL2 (alkaline phosphatase placental / ALP-like 2). | Suzhou, China | Solid tumours | |
Syndivia | ADC developer targeting Undisclosed. | Strasbourg, France | Solid tumours | |
Synthetic Design Lab | ADC developer targeting n/d (multi-target, combinatorial/logic-gated recognition). | South San Francisco, USA | Solid tumours | |
SystImmune / Sichuan Baili (Biokin) | Topoisomerase I inhibitor-payload ADC developer targeting EGFR x HER3 (bispecific). | Redmond, WA, USA | Both | |
T-E Meds | Auristatin + Topo-1 inhibitor-payload ADC developer targeting HER2. | Taipei, Taiwan | Solid tumours | |
T.O.A.D. Oncology SA | ADC developer targeting PSMA (prostate-specific membrane antigen). | Geneva, Switzerland | Solid tumours | |
Tacalyx GmbH | ADC developer targeting TACA (tumor-associated carbohydrate antigen) class - specific antigen not disclosed. | Berlin, Germany | Solid tumours | |
Tagworks Pharmaceuticals BV | Auristatin-payload ADC developer targeting TAG72 (non-internalizing pan-carcinoma marker). | Eindhoven, Netherlands | Solid tumours | |
Taiho Pharmaceutical Co., Ltd. | ADC developer targeting CD79b. | Tokyo, Japan | Haematology | |
Takeda Pharmaceutical Company Limited | Maytansinoid-payload ADC developer targeting Folate receptor alpha (FRa). | Tokyo, Japan | Both | |
Tanabe Pharma Corporation | ADC developer targeting n/d (novel tumor antigen via GV20 STEAD AI platform). | Osaka, Japan | Solid tumours | |
Transcenta (Transcenta Holding Ltd, 创胜集团) | Topo-I-payload ADC developer targeting LIV-1 (SLC39A6). | Suzhou, China | Solid tumours | |
TriOar | N-payload ADC developer targeting n/d - undisclosed. | Seoul, South Korea | Solid tumours | |
Triphase Accelerator Corporation | Maytansinoid-payload ADC developer targeting CD22. | Toronto, ON, Canada | Haematology | |
Tubulis GmbH | Topoisomerase I inhibitor-payload ADC developer targeting NaPi2b. | Munich, Germany | Solid tumours | |
VALANX Biotech | N-payload ADC developer targeting LIV-1 (SLC39A6). | Vienna, Austria | Solid tumours | |
Var2 Pharmaceuticals | Auristatin-payload ADC developer targeting Oncofetal chondroitin sulfate (ofCS). | Copenhagen, Denmark | Solid tumours | |
VelaVigo | Bispecific ADC developer targeting Nectin-4 x TROP2. | Shanghai, China | Solid tumours | |
Vincerx Pharma, Inc. | Kinesin spindle protein-payload ADC developer targeting CD123. | Palo Alto, CA, USA | Haematology | |
Whitehawk Therapeutics, Inc. | N-payload ADC developer targeting PTK7 (Protein Tyrosine Kinase 7). | Morristown, NJ, USA | Solid tumours | |
Zai Lab Limited | Topoisomerase I inhibitor-payload ADC developer targeting DLL3. | Shanghai, China | Solid tumours | |
Zhejiang Medicine Co., Ltd. | Auristatin-payload ADC developer targeting HER2. | Shaoxing, China | Solid tumours | |
Zhejiang Teruisi Pharmaceutical Inc. | Auristatin-payload ADC developer targeting CD20. | China | Haematology | |
Zydus Lifesciences Ltd | Maytansinoid-payload ADC developer targeting HER2. | Ahmedabad, India | Solid tumours | |
Zymeworks Inc. | Topoisomerase-1 inhibitor-payload ADC developer targeting Folate receptor alpha (FR-alpha). | Vancouver, BC, Canada | Solid tumours |
3H (Shanghai) Pharmaceuticals
Auristatin-payload ADC developer targeting FGFR2b.
Shanghai, China
AbbVie
Maytansinoid-payload ADC developer targeting Folate receptor alpha (FRa/FOLR1).
North Chicago, USA
ABL Bio / NEOK Bio
Topoisomerase-1 inhibitor-payload ADC developer targeting B7-H3 x ROR1 (bispecific).
Seongnam, South Korea
AbTis / Dong-A ST
ADC developer targeting CLDN18.2 (Claudin-18.2).
Seoul, South Korea
ADC Therapeutics SA
PBD-payload ADC developer targeting CD19.
Epalinges, Switzerland
Adcendo ApS
Topoisomerase I inhibitor-payload ADC developer targeting uPARAP / Endo180.
Copenhagen, Denmark
Adcentrx Therapeutics
Auristatin-payload ADC developer targeting Nectin-4.
San Diego, CA, USA
Adcytherix SAS
Topo-I-payload ADC developer targeting Undisclosed.
Marseille, France
Aimed Bio
Topoisomerase-I inhibitor-payload ADC developer targeting n/d (undisclosed solid-tumor target).
Seoul, South Korea
Akari Therapeutics
Spliceosome modulator - novel cytotoxic mechanism distinct from tubulin-payload ADC developer targeting Trop2.
London, UK
Akeso Inc
N-payload ADC developer targeting Trop2 / Nectin4 (bispecific).
Zhongshan, Guangdong, China
Alentis Therapeutics
Tubulin inhibitor-payload ADC developer targeting Claudin-1 (CLDN1).
Basel, Switzerland
Allink Bio (Shanghai Allink Biotherapeutics Co., Ltd.)
ADC developer targeting EGFR / cMET (bispecific).
Shanghai, China
Alphamab Oncology
Topoisomerase I inhibitor-payload ADC developer targeting HER2 (biparatopic - two non-overlapping epitopes).
Suzhou, Jiangsu, China
Alteogen, Inc.
Auristatin-payload ADC developer targeting HER2.
Daejeon, South Korea
ALX Oncology Inc.
Topoisomerase I inhibitor-payload ADC developer targeting EGFR.
South San Francisco, USA
Ambrx, Inc.
Microtubule inhibitor-payload ADC developer targeting HER2.
San Diego, USA
AmMax Bio
Topoisomerase-1 inhibitor-payload ADC developer targeting n/d (AmMax proprietary monoclonal antibody; target antigen undisclosed).
Redwood City, CA, USA
Angiex
Microtubule inhibitor-payload ADC developer targeting TM4SF1.
Cambridge, MA, USA
Antengene Corporation
Auristatin-payload ADC developer targeting Claudin 18.2 (CLDN18.2).
Shanghai, China
Antikor Biopharma
Auristatin-payload ADC developer targeting HER2.
Stevenage, UK
Araris Biotech
Auristatin-payload ADC developer targeting CD79b.
Wadenswil, Switzerland
ArriVent BioPharma
ADC developer targeting n/d (genuinely undisclosed in all primary/trade sources checked; GI-focused).
Newtown Square, PA, USA
Astellas Pharma Inc.
Auristatin-payload ADC developer targeting Nectin-4.
Tokyo, Japan
AstraZeneca
Topoisomerase I inhibitor-payload ADC developer targeting HER2 (ERBB2).
Cambridge, UK
Auricula Biosciences, Inc.
N-payload ADC developer targeting n/d - patient population is defined as KRAS-mutant solid tumors, but the antibody's actual cell-surface target antigen is not disclosed in any source found (KRAS itself is intracellular and not a plausible direct ADC binding target).
USA
Avenzo Therapeutics, Inc.
ADC developer targeting EGFR/HER3 (bispecific).
San Diego, USA
Axcynsis Therapeutics Pte Ltd
DNA-binding-payload ADC developer targeting CLDN6.
Singapore, Singapore
BeiGene (BeOne Medicines)
Topoisomerase I inhibitor-payload ADC developer targeting B7-H4.
Beijing, China
BigHat Biosciences, Inc.
ADC developer targeting CDH17.
Menlo Park, USA
Bio-Thera Solutions
Topoisomerase I inhibitor-payload ADC developer targeting Folate receptor alpha (FR-alpha).
Guangzhou, China
BioAtla, Inc.
Auristatin-payload ADC developer targeting AXL.
San Diego, USA
BIOCAD
Maytansinoid-payload ADC developer targeting HER2.
St. Petersburg, Russia
BioCity Biopharmaceutics Co., Ltd.
N-payload ADC developer targeting CDH3 (Cadherin-3 / P-cadherin).
Wuxi, Jiangsu, China
Biocytogen (百奥赛图)
Topoisomerase I inhibitor-payload ADC developer targeting B7H3 / PTK7 (bispecific).
Beijing, China
BiOneCure Therapeutics, Inc.
Bispecific ADC developer targeting TROP2.
Germantown, MD, USA
BioNTech SE
Topoisomerase I inhibitor-payload ADC developer targeting HER2.
Mainz, Germany
BlissBio (Bliss Biopharmaceutical (Hangzhou) Co., Ltd.)
Eribulin-payload ADC developer targeting HER2.
Hangzhou, Zhejiang, China
Boan Biotech
Auristatin-payload ADC developer targeting Claudin 18.2 (CLDN18.2).
Yantai, Shandong, China
Boehringer Ingelheim
Topo-I-payload ADC developer targeting Undisclosed (described as playing a significant role in tumor growth, metastasis and therapeutic resistance across multiple malignancies).
Ingelheim, Germany
Bristol Myers Squibb
Topoisomerase I inhibitor-payload ADC developer targeting EGFR x HER3 (bispecific).
Princeton, USA
Byondis B.V.
Duocarmycin-payload ADC developer targeting HER2.
Nijmegen, Netherlands
Callio Therapeutics
Dual-payload-payload ADC developer targeting HER2.
Seattle, WA, USA
Cantargia
Tubulin inhibitor-payload ADC developer targeting IL1RAP.
Lund, Sweden
CatenaBio
Dual: tubulin inhibitor and topo-1 inhibitor-payload ADC developer targeting TROP2.
Berkeley, CA, USA
Celltrion
Topoisomerase-I inhibitor-payload ADC developer targeting Nectin-4.
Incheon, South Korea
Changchun GeneScience Pharmaceutical Co., Ltd.
ADC developer targeting EGFR x HER2 (bispecific).
Changchun, China
Chengdu Kanghong Pharmaceutical Group / Kanghong Biotechnology
Dual: topoisomerase-1 inhibitor + RNA-polymerase-II inhibitor-payload ADC developer targeting TROP2 (single cell-surface antibody target; two distinct intracellular payload mechanisms).
Chengdu, China
Chia Tai Tianqing (CTTQ) / Sino Biopharmaceutical
Topoisomerase I inhibitor-payload ADC developer targeting HER2 (biparatopic - two distinct extracellular domain epitopes, ECD2 and ECD4).
Hong Kong, China
Chiome Bioscience Inc.
PBD-payload ADC developer targeting DLK1.
Tokyo, Japan
Chong Kun Dang
ADC developer targeting c-MET.
Seoul, South Korea
Chugai Pharmaceutical Co., Ltd.
ADC developer targeting n/d (one Chugai-selected target, undisclosed).
Tokyo, Japan
CIS Biopharma
Topo-1 inhibitor-payload ADC developer targeting CD171/L1CAM.
Bubendorf, Switzerland
Corbus Pharmaceuticals Holdings, Inc.
Auristatin-payload ADC developer targeting Nectin-4.
Norwood, MA, USA
Crescent Biopharma
ADC developer targeting ITGB6 (integrin beta-6).
Waltham, MA, USA
CrossBridge Bio
Dual: topo-1 inhibitor-payload ADC developer targeting TROP2.
Houston, TX, USA
CSPC Pharmaceutical Group (Megalith / ZhongQi / Ouyi / Innovation)
Auristatin-payload ADC developer targeting EGFR.
Shijiazhuang, Hebei, China
CStone Pharmaceuticals
PBD-payload ADC developer targeting ROR1.
Suzhou, China
CytomX Therapeutics, Inc.
Maytansinoid-payload ADC developer targeting CD166.
South San Francisco, USA
Daiichi Sankyo Co., Ltd.
Global ADC leader with the largest DXd (topoisomerase-1) franchise: two approved products in HER2 and TROP2 and a deep next-generation pipeline
Tokyo, Japan
Day One Biopharmaceuticals, Inc.
Auristatin-payload ADC developer targeting B7-H4.
South San Francisco, USA
Debiopharm
ADC developer targeting HER3/HER2 (bispecific).
Lausanne, Switzerland
DualityBio (Duality Biologics)
Topoisomerase I inhibitor-payload ADC developer targeting HER2.
Shanghai, China
Earendil Labs
Topoisomerase I inhibitor-payload ADC developer targeting CEACAM5 / CDH17 (bispecific).
Unconfirmed, China
Eisai Co., Ltd.
Eribulin-payload ADC developer targeting Folate receptor alpha (FRα).
Tokyo, Japan
Elevation Oncology
Auristatin-payload ADC developer targeting Claudin 18.2 (CLDN18.2).
New York, NY, USA
Eli Lilly and Company
Topoisomerase I inhibitor-payload ADC developer targeting Nectin-4.
Indianapolis, IN, USA
Ellipses Pharma Ltd
Eribulin-payload ADC developer targeting B7H3.
London, UK
Emergence Therapeutics AG
Topo-I-payload ADC developer targeting Nectin-4.
Duisburg, Germany
Endeavor BioMedicines, Inc.
ADC developer targeting HER3.
San Diego, USA
Evopoint Biosciences Co., Ltd.
Topoisomerase I inhibitor-payload ADC developer targeting Claudin 18.2 (CLDN18.2).
Suzhou, China
Exelixis, Inc.
Auristatin-payload ADC developer targeting 5T4.
Alameda, CA, USA
Experimental Drug Development Centre (EDDC), A*STAR
Auristatin-payload ADC developer targeting Tumor-specific N-glycosylated epitope conserved on CEACAM5 and CEACAM6.
Singapore, Singapore
Foreseen Biotechnology
Topoisomerase I inhibitor-payload ADC developer targeting n/d (undisclosed novel tumor-associated antigen, identified via AI-powered proteomics screening).
Unconfirmed, China
Fosun Pharma (Shanghai Fosun Pharmaceutical Group)
Auristatin-payload ADC developer targeting HER2.
Shanghai, China
GeneQuantum Healthcare
Topoisomerase I inhibitor-payload ADC developer targeting HER2.
Suzhou, China
Genmab A/S
Auristatin-payload ADC developer targeting Tissue Factor (TF/F3).
Copenhagen, Denmark
Genome and Company
Auristatin-payload ADC developer targeting BCAM (CD239).
Seongnam, South Korea
Gilead Sciences, Inc.
Topoisomerase I inhibitor-payload ADC developer targeting Trop-2 (TACSTD2).
Foster City, CA, USA
Glenmark Pharmaceuticals Ltd / Ichnos Glenmark Innovation (IGI)
Topoisomerase I inhibitor-payload ADC developer targeting HER2.
Mumbai, India
GlycoNex
ADC developer targeting Branched Lewis B/Y (bLeB/Y) tumor-associated glycan.
Hsinchu, Taiwan
Glykos Finland
Auristatin-payload ADC developer targeting CD33.
Espoo, Finland
GSK
Auristatin-payload ADC developer targeting BCMA (TNFRSF17).
London, UK
Hangzhou Adcoris Biopharma
Topoisomerase I inhibitor-payload ADC developer targeting 5T4 (TPBG).
Hangzhou, China
Hangzhou DAC Biotech
Topoisomerase I inhibitor-payload ADC developer targeting CD56 (NCAM1).
Hangzhou, China
Hanmi Pharmaceutical (Beijing)
Topoisomerase-I inhibitor-payload ADC developer targeting PD-L1 x B7-H3 (tetravalent bispecific).
Beijing, China
Hansoh Pharma
Topoisomerase I inhibitor-payload ADC developer targeting B7-H3.
Lianyungang, China
Harbour BioMed (HBM Holdings) / Nona Biosciences
Topoisomerase I inhibitor-payload ADC developer targeting Mesothelin (MSLN).
Shanghai, China
Heidelberg Pharma AG
Amanitin-payload ADC developer targeting BCMA.
Ladenburg, Germany
Huadong Medicine (Hangzhou Zhongmei Huadong Pharmaceutical)
Maytansinoid-payload ADC developer targeting Folate receptor alpha (FRalpha).
Hangzhou, China
Hummingbird Bioscience Pte Ltd
Topoisomerase I inhibitor-payload ADC developer targeting HER3.
Singapore, Singapore
IDEAYA Biosciences, Inc.
Topoisomerase I inhibitor-payload ADC developer targeting DLL3.
South San Francisco, CA, USA
Iksuda Therapeutics Ltd.
PBD-payload ADC developer targeting CD19.
Newcastle upon Tyne, England, UK
Immunome, Inc.
Topoisomerase I inhibitor-payload ADC developer targeting ROR1.
Bothell, WA, USA
Inatherys
ADC developer targeting CD71 / transferrin receptor 1 (TfR1).
Evry-Courcouronnes, France
Innate Pharma
Topo-I-payload ADC developer targeting Nectin-4.
Marseille, France
InnoCare Pharma
N-payload ADC developer targeting CDH17 (cadherin-17).
Beijing, China
Innolake Biopharm (英诺湖医药)
Eribulin-payload ADC developer targeting B7-H3 (CD276).
Hangzhou, China
Innovent Biologics
Topoisomerase I inhibitor-payload ADC developer targeting CLDN18.2.
Suzhou, China
Inspirna
Auristatin-payload ADC developer targeting MERTK (MER proto-oncogene tyrosine kinase).
New York, NY, USA
IntoCell
Duocarmycin-payload ADC developer targeting B7-H3.
Seongnam, South Korea
InxMed (Ying Shi Bio)
Topoisomerase I inhibitor-payload ADC developer targeting Integrin alphaVbeta6 (ITGB6).
Shanghai, China
Ipsen
Topo-I-payload ADC developer targeting LRRC15.
Paris, France
Jiangsu Hengrui Pharmaceuticals (Hengrui Medicine / Hengrui Pharma)
Topoisomerase I inhibitor-payload ADC developer targeting HER2 (ERBB2).
Shanghai, China
Johnson & Johnson (Janssen)
Auristatin-payload ADC developer targeting HER2 (ERBB2).
New Brunswick, NJ, USA
Junshi Biosciences (Shanghai Junshi Bioscience Co., Ltd.)
Tubulin inhibitor-payload ADC developer targeting Claudin 18.2 (CLDN18.2).
Shanghai, China
Kanaph Therapeutics
ADC developer targeting cMET x EGFR (bispecific).
Seoul, South Korea
Kelun-Biotech (Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)
Topoisomerase I inhibitor-payload ADC developer targeting TROP2 (TACSTD2).
Chengdu, Sichuan, China
KeyMed Biosciences
Auristatin-payload ADC developer targeting Claudin 18.2 (CLDN18.2).
Chengdu, China
Kivu Bioscience Inc.
Topoisomerase I inhibitor-payload ADC developer targeting PTK7.
San Francisco, USA
Kyinno Biotechnology (凯茵诺生物)
Topoisomerase I inhibitor-payload ADC developer targeting EGFR / MET (bispecific).
Unconfirmed, China
Kyowa Kirin Co., Ltd.
PBD-payload ADC developer targeting TIM-3.
Tokyo, Japan
LaNova Medicines
Auristatin-payload ADC developer targeting Claudin 18.2 (CLDN18.2).
Shanghai, China
Lepu Biopharma Co., Ltd.
Auristatin-payload ADC developer targeting EGFR.
Shanghai, China
LigaChem Biosciences, Inc.
Auristatin-payload ADC developer targeting TROP2.
Daejeon, South Korea
MabCare Therapeutics
ADC developer targeting PTK7.
Shanghai, China
Mablink Bioscience
ADC developer targeting Folate receptor alpha (FRa).
Lyon, France
Mabsoft Therapeutics (Shanghai) Co., Ltd.
N-payload ADC developer.
Shanghai, China
Mabwell (Shanghai Mabwell Bioscience Co., Ltd.)
Auristatin-payload ADC developer targeting Nectin-4.
Shanghai, China
MacroGenics, Inc.
Topoisomerase I inhibitor-payload ADC developer targeting B7-H3.
Rockville, MD, USA
MBrace Therapeutics, Inc.
Auristatin-payload ADC developer targeting EphA5.
San Diego, CA, USA
MediLink Therapeutics (Suzhou) Co., Ltd.
Topoisomerase I inhibitor-payload ADC developer targeting B7-H3.
Suzhou, China
Menarini Ricerche S.p.A.
Maytansinoid-payload ADC developer targeting CD205 (Ly75).
Pomezia, Italy
Merck & Co., Inc. (MSD outside US/Canada)
Topoisomerase I inhibitor-payload ADC developer targeting TROP2.
Rahway, NJ, USA
Merck KGaA, Darmstadt
Topo-I-payload ADC developer targeting CEACAM5.
Darmstadt, Germany
Mersana Therapeutics
Auristatin-payload ADC developer targeting B7-H4.
Cambridge, MA, USA
Merus
Antibody-drug conjugate developer.
Utrecht, Netherlands
Minghui Pharmaceutical Ltd.
Topoisomerase I inhibitor-payload ADC developer targeting B7-H3.
Hangzhou, China
Multitude Therapeutics
Topoisomerase I inhibitor-payload ADC developer targeting CD44v9.
Unconfirmed, China
Myricx Bio
NMTi - novel-payload ADC developer targeting B7-H3.
London, UK
Mythic Therapeutics, Inc.
Auristatin-payload ADC developer targeting cMET.
Waltham, MA, USA
Nanjing Leads Biolabs (南京维立志博)
Topoisomerase I inhibitor-payload ADC developer targeting CDH17.
Nanjing, Jiangsu, China
Nanolattix Biotechnology Co., Ltd.
ADC developer targeting Tissue Factor (TF).
China
Navrogen, Inc.
N-payload ADC developer targeting Mesothelin (MSLN).
Cheyney, PA, USA
NextCure, Inc.
Topoisomerase I inhibitor-payload ADC developer targeting B7-H4.
Beltsville, MD, USA
Novartis
NMT inhibitor - novel cytotoxic payload class disrupting protein myristoylation-payload ADC developer targeting B7-H3.
Basel, Switzerland
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.
Auristatin-payload ADC developer targeting c-Met / EGFR (bispecific).
Zhejiang province, China
Novelty Nobility, Inc.
Auristatin-payload ADC developer targeting c-Kit (CD117).
Seoul, South Korea
OBI Pharma, Inc.
Topoisomerase I inhibitor-payload ADC developer targeting TROP2.
Taipei, Taiwan
Ona Therapeutics
Tubulin inhibitor-payload ADC developer targeting Confidential (highly expressed in HR+/HER2- breast cancer; upregulated in treatment-resistant tumors).
Barcelona, Spain
Oncomatryx Biopharma S.L.
Synthetic cytolysin-payload ADC developer targeting FAP (Fibroblast Activation Protein) - cancer-associated-fibroblast/tumor-microenvironment target.
Derio, Bizkaia, Spain
OnCusp Therapeutics, Inc.
Topoisomerase I inhibitor-payload ADC developer targeting CDH6.
Princeton, NJ, USA
Ono Pharmaceutical Co., Ltd.
ADC developer targeting L1CAM (L1 cell adhesion molecule).
Osaka, Japan
Oqory, Inc.
ADC developer targeting TROP2.
San Diego, CA, USA
Peptron
ADC developer targeting MUC1.
Daejeon, South Korea
Pfizer Inc.
Auristatin-payload ADC developer targeting Nectin-4.
New York, NY, USA
Pheon Therapeutics
ADC developer targeting n/d (internalizable single-pass transmembrane protein, highly over-expressed in multiple solid tumors, low healthy-tissue expression).
London, UK
PinotBio
Topo-1 inhibitor-payload ADC developer targeting Trop2.
Seongnam, South Korea
Prestige Biopharma IDC
N-payload ADC developer targeting n/d - undisclosed.
Seoul, South Korea
Pyramid Biosciences
Topoisomerase I inhibitor-payload ADC developer targeting TROP2.
Boston, MA, USA
Pyxis Oncology, Inc.
ADC developer targeting Extradomain-B of fibronectin (EDB+FN) - an extracellular-matrix, non-cellular structural antigen.
Boston, MA, USA
Qilu Pharmaceutical Co., Ltd.
Topoisomerase I inhibitor-payload ADC developer targeting Claudin 6 (CLDN6).
Jinan, Shandong, China
Qurient Therapeutics
ADC developer targeting n/d - undisclosed.
Seoul, South Korea
Radiance Biopharma, Inc.
Auristatin-payload ADC developer targeting c-MET and EGFR (bispecific).
San Diego, CA area, USA
RemeGen (Yantai RemeGen Co., Ltd.)
Tubulin inhibitor-payload ADC developer targeting HER2 (ERBB2).
Yantai, Shandong, China
Roche / Genentech
Maytansinoid-payload ADC developer targeting HER2.
South San Francisco, CA, USA
Ryvu Therapeutics
Antibody-drug conjugate developer.
Krakow, Poland
Samjin Pharmaceutical
NAMPT inhibitor - non-classical cytotoxic payload class, not on the project's standard example list, but a genuine cytotoxic small molecule per peer-reviewed literature-payload ADC developer targeting HER2.
Seoul, South Korea
Samsung Bioepis Co., Ltd.
ADC developer targeting Nectin-4.
Incheon, South Korea
Sanofi
Topoisomerase I inhibitor-payload ADC developer targeting CEACAM5.
Paris, France
Shandong New Time Pharmaceutical Co., LTD
ADC developer targeting Nectin-4.
Linyi, Shandong, China
Shanghai Affinity Biopharmaceutical Co., Ltd.
ADC developer targeting IL-2 (atypical target for an ADC - IL-2 is normally a soluble cytokine rather than a cell-surface tumor antigen; precise binding mechanism not independently verified).
Shanghai, China
Shanghai Escugen Biotechnology Co., Ltd
ADC developer targeting TROP2.
Shanghai, China
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Topoisomerase I inhibitor-payload ADC developer targeting TROP2.
Shanghai, China
Shanghai Henlius Biotech, Inc.
N-payload ADC developer targeting HER2.
Shanghai, China
Shanghai Huaota Biopharmaceutical Co., Ltd.
ADC developer targeting CD73.
Shanghai, China
Shanghai Runshi Pharmaceutical Technology Co., Ltd
Auristatin-payload ADC developer targeting HER2.
Shanghai, China
Shanghai Tangling Biomedicine
ADC developer targeting TROP-2.
Shanghai, China
Sidewinder Therapeutics
Bispecific ADC developer targeting n/d (dual-targeting design: one undisclosed tumor-driver receptor + one undisclosed internalizing receptor).
San Francisco Bay Area, USA
Simcere Zaiming
Topoisomerase I inhibitor-payload ADC developer targeting CDH6.
Nanjing, China
Solve Therapeutics
ADC developer targeting n/d ('distinct membrane receptor protein selectively expressed on multiple solid-tumor malignancies').
San Diego, CA, USA
Sorrento Therapeutics / Scintilla Pharmaceuticals
Auristatin-payload ADC developer targeting CD38.
San Diego, CA, USA
SOTIO Biotech
ADC developer targeting CDH17 (Cadherin-17).
Prague, Czech Republic
Stipple Bio, Inc.
ADC developer targeting n/d (tumor-specific cell-surface epitope, precise antigen undisclosed).
Cambridge, MA, USA
Sun Pharma Advanced Research Company Ltd (SPARC)
ADC developer targeting MUC1 (SEA domain, targeting the epitope exposed only when both MUC1 alpha and beta chains remain intact).
Mumbai, India
Sutro Biopharma, Inc.
Hemiasterlin-class tubulin-payload ADC developer targeting Folate receptor alpha (FOLR1).
South San Francisco, CA, USA
Suzhou Hepius Therapeutics
Auristatin-payload ADC developer targeting ALPP/ALPPL2 (alkaline phosphatase placental / ALP-like 2).
Suzhou, China
Syndivia
ADC developer targeting Undisclosed.
Strasbourg, France
Synthetic Design Lab
ADC developer targeting n/d (multi-target, combinatorial/logic-gated recognition).
South San Francisco, USA
SystImmune / Sichuan Baili (Biokin)
Topoisomerase I inhibitor-payload ADC developer targeting EGFR x HER3 (bispecific).
Redmond, WA, USA
T-E Meds
Auristatin + Topo-1 inhibitor-payload ADC developer targeting HER2.
Taipei, Taiwan
T.O.A.D. Oncology SA
ADC developer targeting PSMA (prostate-specific membrane antigen).
Geneva, Switzerland
Tacalyx GmbH
ADC developer targeting TACA (tumor-associated carbohydrate antigen) class - specific antigen not disclosed.
Berlin, Germany
Tagworks Pharmaceuticals BV
Auristatin-payload ADC developer targeting TAG72 (non-internalizing pan-carcinoma marker).
Eindhoven, Netherlands
Taiho Pharmaceutical Co., Ltd.
ADC developer targeting CD79b.
Tokyo, Japan
Takeda Pharmaceutical Company Limited
Maytansinoid-payload ADC developer targeting Folate receptor alpha (FRa).
Tokyo, Japan
Tanabe Pharma Corporation
ADC developer targeting n/d (novel tumor antigen via GV20 STEAD AI platform).
Osaka, Japan
Transcenta (Transcenta Holding Ltd, 创胜集团)
Topo-I-payload ADC developer targeting LIV-1 (SLC39A6).
Suzhou, China
TriOar
N-payload ADC developer targeting n/d - undisclosed.
Seoul, South Korea
Triphase Accelerator Corporation
Maytansinoid-payload ADC developer targeting CD22.
Toronto, ON, Canada
Tubulis GmbH
Topoisomerase I inhibitor-payload ADC developer targeting NaPi2b.
Munich, Germany
VALANX Biotech
N-payload ADC developer targeting LIV-1 (SLC39A6).
Vienna, Austria
Var2 Pharmaceuticals
Auristatin-payload ADC developer targeting Oncofetal chondroitin sulfate (ofCS).
Copenhagen, Denmark
VelaVigo
Bispecific ADC developer targeting Nectin-4 x TROP2.
Shanghai, China
Vincerx Pharma, Inc.
Kinesin spindle protein-payload ADC developer targeting CD123.
Palo Alto, CA, USA
Whitehawk Therapeutics, Inc.
N-payload ADC developer targeting PTK7 (Protein Tyrosine Kinase 7).
Morristown, NJ, USA
Zai Lab Limited
Topoisomerase I inhibitor-payload ADC developer targeting DLL3.
Shanghai, China
Zhejiang Medicine Co., Ltd.
Auristatin-payload ADC developer targeting HER2.
Shaoxing, China
Zhejiang Teruisi Pharmaceutical Inc.
Auristatin-payload ADC developer targeting CD20.
China
Zydus Lifesciences Ltd
Maytansinoid-payload ADC developer targeting HER2.
Ahmedabad, India
Zymeworks Inc.
Topoisomerase-1 inhibitor-payload ADC developer targeting Folate receptor alpha (FR-alpha).
Vancouver, BC, Canada
The Full Map
Request a custom market map
Tell us what you need to see. Byron will come back to you personally with a sample of the data and how we'd build out the full picture for your slice of the market.
About this directory
Compiled and maintained by ProGen Search
ProGen Search is an executive search firm specialising in antibody-drug conjugate, radiopharmaceutical, CDMO and biotech leadership hiring. Building or scaling one of the companies on this list? Every entry competes for the same scarce operator-grade leadership: a Head of CMC who has run a conjugation process, a VP of Quality with an FDA inspection behind them, a CSO who has actually shipped an ADC. That market is where ProGen Search works.
ProGen Search Limited, Ground Floor, Techno Centre, Station Road, Horsforth, Leeds, LS18 5BJ. © 2026. For informational purposes only; not investment, legal or medical advice. Compiled from public sources as of 2026 and may have changed.